# EDGAR Filing Document

**Accession Number:** 0001722964
**File Stem:** 0001104659-25-093587
**Filing Date:** 2025-9
**Character Count:** 2810
**Document Hash:** fda21708d4405611f9db2288b10b0f2d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-093587.hdr.sgml**: 20250926

**ACCESSION NUMBER**: 0001104659-25-093587

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250926

**DATE AS OF CHANGE**: 20250926

**EFFECTIVENESS DATE**: 20250926

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Y-mAbs Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001722964
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474619612
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38650
- **FILM NUMBER:** 251345503

**BUSINESS ADDRESS:**
- **STREET 1:** 202 CARNEGIE CENTER
- **STREET 2:** SUITE 301
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** 646-885-8505

**MAIL ADDRESS:**
- **STREET 1:** 202 CARNEGIE CENTER
- **STREET 2:** SUITE 301
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION**

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934**

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number: 001-38650

**Y-MABS THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**202 Carnegie Center, Suite 301**

**Princeton, New Jersey 08540**

**(646) 885-8505**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Common Stock, par value $0.0001 per share**

(Title of each class of securities covered by this Form)

**None**

(Title of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ⌧ |
| Rule 12g-4(a)(2) | ◻ |
| Rule 12h-3(b)(1)(i) | ⌧ |
| Rule 12h-3(b)(1)(ii) | ◻ |
| Rule 15d-6 | ◻ |
| Rule 15d-22(b) | ◻ |

---

Approximate number of holders of record as of the certification or notice date: One

Pursuant to the requirements of the Securities Exchange Act of 1934, Y-mAbs Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
|  | **Y-MABS THERAPEUTICS, INC.** | **Y-MABS THERAPEUTICS, INC.** |
| September 26, 2025 | By: | /s/ Vanessa Wolfeler |
|  | Name: Vanessa Wolfeler | Name: Vanessa Wolfeler |
|  | Title: President | Title: President |

---